Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Affymax Earns Takeda Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Affymax Earns Takeda Milestone

FDA Approves Omontys Injection

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Affymax has received a $50 million development milestone payment from Takeda Pharmaceutical Co., triggered by the FDA approval of Omontys (peginesatide) Injection. Affymax also received a $5 million milestone payment triggered by the EMA acceptance of the MAA back in February.

In 2006, the companies entered an exclusive global agreement to develop and commercialize Omontys Injection. Both companies are working together to commercialize Omontys in the U.S. Takeda holds an exclusive license to develop and commercialize the product outside the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics